No Data
No Data
Castle Biosciences to Present Research on Melanoma Patient Care at AACR Annual Meeting 2025
New Data at AACR Annual Meeting Highlights Use of DecisionDx-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
Express News | Castle Biosciences Inc : Leerink Partners Cuts Target Price to $35 From $40
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
Castle Biosciences Honored With a Top Workplaces USA Award for Fourth Consecutive Year